Icotyde is icotrokinra, an FDA-approved oral medicine for moderate to severe plaque psoriasis. It is a regulated prescription tablet, not an injectable biologic or an unregulated research peptide.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Icotyde is icotrokinra, an FDA-approved oral medicine for moderate to severe plaque psoriasis. It is a regulated prescription tablet, not an injectable biologic or an unregulated research peptide. The current US label is revised March 2026.
Icotrokinra blocks the IL-23 receptor, a pathway involved in psoriasis inflammation. It can reduce plaques and symptoms over time. It does not provide a general indication for every inflammatory skin or joint condition.
The indication includes adults and children age 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. Confirm the diagnosis, affected sites, severity and prior treatment. The US label does not include psoriatic arthritis, so joint symptoms need separate assessment.
The label uses 200 mg orally once daily on waking, on an empty stomach with water, waiting at least 30 minutes before food. Swallow whole; for difficulty swallowing, the label has specific water-dispersion instructions to review with the clinician or pharmacist. Do not improvise crushing or dose changes.
Bring skin photos, prior treatments, medicines and infection and vaccination history. Consider TB evaluation based on clinical judgment and complete age-appropriate vaccinations before treatment. Discuss kidney disease, pregnancy and breastfeeding. Confirm ongoing pharmacy access and follow-up before relying on a sample.
Report infection symptoms and serious hypersensitivity. Avoid live vaccines during treatment. The label advises monitoring for potential adverse reactions in patients with eGFR below 60. A severe widespread rash or new painful swollen joints deserves reassessment rather than assuming all symptoms are plaque psoriasis.
Review skin clearance, itch, difficult sites, function and adverse effects at agreed intervals. Clinical trial improvement at weeks 16 or 24 does not predict an exact personal result. If symptoms persist or the dosing routine is difficult, discuss the plan rather than increasing the dose.
Confirm the clinician and pharmacy route before starting. Visit coverage does not guarantee medication coverage, and manufacturer support or a sample does not guarantee affordable refills. Ask about authorization, testing, costs and follow-up. Confirm whether the selected clinic prescribes the product and whether the pharmacy can fill the exact dose.
The indication includes adults and children age 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. Confirm the diagnosis, affected sites, severity and prior treatment. The US label does not include psoriatic arthritis, so joint symptoms need separate assessment.
Bring skin photos, prior treatments, medicines and infection and vaccination history. Consider TB evaluation based on clinical judgment and complete age-appropriate vaccinations before treatment. Discuss kidney disease, pregnancy and breastfeeding. Confirm ongoing pharmacy access and follow-up before relying on a sample.
Icotyde is icotrokinra, an FDA-approved oral IL-23 receptor antagonist for qualifying plaque psoriasis. It is taken as a tablet under specific fasting instructions, rather than as an injectable biologic. It is not a research-use peptide product. Use the prescribed regulated product and review its age, weight, infection and vaccination requirements.
Icotyde’s US indication is moderate-to-severe plaque psoriasis in adults and children age 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. It does not have a reviewed US psoriatic-arthritis indication. New joint swelling, stiffness or pain needs assessment and may need a different treatment plan.
Improvement varies, and the Icotyde plaque-psoriasis studies assessed key skin responses at 16 weeks. That study time point is not a promise of complete clearance or a reason to change the dose yourself. Agree on a review interval and track skin involvement, itch, difficult sites and adverse effects; persistent symptoms may change the plan.
A sample does not remove the need to confirm diagnosis, suitability, safety and affordable continuation. Ask the prescriber how refills will be obtained if authorization remains pending or is denied. Do not assume a sample proves insurance approval or that treatment can continue without interruption.
Before treatment starts, confirm the diagnosis, the intended benefit, the exact treatment and who will coordinate ongoing care. The label uses 200 mg orally once daily on waking, on an empty stomach with water, waiting at least 30 minutes before food. Swallow whole; for difficulty swallowing, the label has specific water-dispersion instructions to review with the clinician or pharmacist. Do not improvise crushing or dose changes.
Prepare the relevant dated records, current medicine list and your main questions, and confirm any treatment-specific instructions before attending. Bring skin photos, prior treatments, medicines and infection and vaccination history. Consider TB evaluation based on clinical judgment and complete age-appropriate vaccinations before treatment. Discuss kidney disease, pregnancy and breastfeeding. Confirm ongoing pharmacy access and follow-up before relying on a sample.
Agree on the next review, how response and safety will be checked, and who to contact for symptoms, missed treatment or a refill problem. Review skin clearance, itch, difficult sites, function and adverse effects at agreed intervals. Clinical trial improvement at weeks 16 or 24 does not predict an exact personal result. If symptoms persist or the dosing routine is difficult, discuss the plan rather than increasing the dose.
Icotrokinra is FDA-approved in the United States as Icotyde; the manufacturer announced approval in March 2026. It is a regulated oral tablet for qualifying moderate-to-severe plaque psoriasis in adults and children age 12 or older who weigh at least 40 kg. Approval does not establish that your pharmacy has stock, your plan has authorized it or a particular clinic prescribes it. Confirm those steps with the prescriber and dispensing pharmacy before relying on a start date. A research-use peptide product is not a substitute for the approved prescription.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
